I
n the 1980s and 1990s, HIV infection inevitably (with a few rare exceptions) led to multiple opportunistic complications and premature death. Pneumocystis pneumonia, toxoplasma encephalitis, cryptococcal meningitis, cytomegalovirus retinitis, pneumococcal bacteremia, Kaposi sarcoma, and lymphoma were recurrent complications that led most patients to die within a decade of their initial AIDS diagnosis. These opportunistic processes still occur in persons who are not aware of their HIV infection or persons who are not taking antiretroviral therapy (ART) due to social, economic, or mental health challenges.
In this current decade, the prospects for persons with HIV infection are much more sanguine. About half of the 1.1 million persons living in the United States have achieved the effective, long-term HIV suppression that correlates with prolonged survival (1) (2) (3) . The number of persons living with HIV in the United States is not likely to fall in the next decade; since in 2014, there were 37,600 new cases of HIV infection and 6,721 deaths, a net gain of over 30,000 prevalent cases. Furthermore, the life expectancy of persons with HIV infection who are successfully treated with ART is projected to exceed 70 years suggesting that such HIV-infected persons will have almost normal life expectancies, although that life expectancy may be affected by specific HIV-related morbidities (2) .
With at least 600,000 persons with HIV on effective longterm ART in the United States (3), intensivists can expect to see HIV-infected patients in their ICUs for trauma, postoperative care, routine medical maladies, and the expected consequences of aging. HIV-infected persons on effective ART may in fact be overrepresented in ICUs because they have more than the expected morbidities due to their "accelerated aging," which is a consequence of low-level chronic HIV viremias (despite ART) that produces an ongoing state of enhanced inflammation. This enhanced inflammation accelerates their development of cardiovascular, cerebrovascular, hepatic, renal and malignant neoplastic diseases (4).
PRINCIPLES OF ART IN CRITICALLY ILL PATIENTS
The miraculous development of highly effective antiretrovirals has transformed HIV infection from an inevitably fatal disease to a chronic process with an almost normal quality of life. The U.S. Food and Drug Administration has approved more than two dozen separate drugs representing six different drug classes (5) . However, these advances have been associated with added levels of complexity regarding their use, especially in critically ill patients, because of multiple drug interactions and the risks associated with starting, stopping, or inappropriately dosing these therapies. As such, management decisions regarding ART are increasingly complex: infectious disease physicians and pharmacists can often add considerable strategic expertise to decisions in the ICU about the initiation, continuation, or discontinuation of ART.
or drug class, that resistance persists lifelong. Virtually, all commonly used antiretroviral drugs are only available as oral formulations. Administration by this oral route in critically ill patients can lead to subtherapeutic drug levels and lifelong antiretroviral resistance. This lifelong resistance occurs because mutations in this virus become archived in cellular DNA. Crushing tablets to put them down feeding tubes presents multiple additional dimensions of unpredictable delivery and absorption. Thus, in patients who are postoperative, or patients who are intubated, maintaining predictable and adequate plasma levels of drugs poses a challenge. Strategies to maintain appropriate drug levels are important to attempt. However, in some situations involving uncertain gastrointestinal absorption that is likely to persist over several days or more, or inability to administer oral agents even through a feeding tube, ART should be stopped altogether since the absence of drug removes the selective pressure which drives antiretroviral resistance. Although there are a wider variety of drugs available with different mechanisms of action compared with 15 years ago, patients who will be on lifelong ART for decades cannot afford to lose whole classes of drugs due to suboptimal therapeutic decisions. Stopping drugs to prevent the emergence of resistance, however, can be challenging and should be assessed on a case-by-case basis. Discontinuation of multidrug or single tablet regimens when the individual component drugs have different half-lives can lead to periods when only one drug has measurable plasma levels, again increasing the probability of creating lifelong resistance. This problem is most notorious for Atripla (Gilead Sciences, Foster City, CA) (the combination oral tablet of efavirenz, tenofovir disoproxil, and emtricitabine) since the efavirenz component has a longer half-life (55 hr) compared with tenofovir (17 hr) or emtricitabine (10 hr). Thus, if Atripla is stopped, patients effectively receive efavirenz monotherapy for many days after the tenofovir and emtricitabine have been eliminated. This unintended monotherapy promotes the emergence of resistance even over a period of days. There is not, however, a validated and standardized strategy to minimizing this risk, but some plausible approach needs to be used.
There is the prospect that an injectable antiretroviral regimen may be available in the future. Long-acting intramuscular injections of cabotegravir and rilpivirine are currently being studied as every 4-or 8-week injections for chronic maintenance therapy. However, the safety, efficacy, pharmacokinetics, and potential drug interactions of such regimens in critically ill patients need to be carefully studied before they can be recommended for use in an ICU (6).
LIFE-THREATENING COMPLICATIONS OF ART
Of the antiretroviral agents recommended in current guidelines, most are extremely well tolerated, but some serious complications may develop that could lead to ICU admission. Fortunately, many of the most toxic drugs in the 1990s, such as didanosine or stavudine (D4T), that were associated with pancreatitis, neuropathy, and/or lactic acidosis are no longer marketed in the United States (7). More effective and less toxic options have been developed. Two currently used drugs deserve special mention. Abacavir can cause distributive shock that may present like sepsis. This complication occurs exclusively in those patients expressing human leukocyte antigen-B*5701. This syndrome is less likely to occur when providers test patients for HLA-B*5701 prior to therapy, but some providers may have prescribed these drugs without taking this precaution. Within 6 weeks of starting this drug, patients can present with a nonspecific febrile illness that includes fatigue, nausea, vomiting, pulmonary infiltrates, and/ or skin rash (8) . Some patients stop taking their abacavir due to nausea or malaise, but then restart the drug when they feel better. This "rechallenge" can elicit a severe hypersensitivity reaction that causes distributive shock and bronchospasm that has been associated with fatal outcomes (9) . Therapy is supportive after the drug is stopped.
Raltegravir has been associated with rhabdomyolysis which has occurred as early as 10 days and as late as 22 months after initiation of therapy. To date, these episodes have not been fatal, but creatinine kinase rises can be substantial (10, 11) . It remains to be seen whether this syndrome is specific for this particular drug, or whether this is a classrelated phenomenon which will be observed with all of these agents which currently dominate the preferred regimens that guidelines recommend.
DRUG INTERACTIONS ASSOCIATED WITH ART
The CYP450 enzyme system is the most common pathway for hepatic metabolism of drugs, affecting many drugs that are used in the ICU, including certain sedatives, hypnotics, anticonvulsants, anticoagulants, antiarrhythmics, analgesics, and antipsychotics. Although many types of drug interactions involving ART can occur, the most prominent involve CYP450 inhibitors. Pharmacokinetic enhancers, cobicistat and ritonavir, are administered or coformulated with antiretroviral drugs to boost plasma concentrations by inhibiting CYP3A4 metabolism. Although they are very effective in optimizing the pharmacokinetics of ART, they also have substantial boosting effects on many other drugs, including sedatives, analgesics, anticoagulants, antipsychotics, anticonvulsants, and antiarrhythmics. Thus, if these medications are administered in the ICU to patients who are on protease inhibitors, cobicistat, or ritonavir containing ART, exaggerated effects of the target drugs and/or enhanced toxicities may occur (Supplementary  Table 1 , Supplemental Digital Content 1, http://links.lww.com/ CCM/D327).
Efavirenz is an example of another antiretroviral agent that can cause complicated drug interactions as it can induce the metabolism of medications which are metabolized via CYP3A4. For instance, efavirenz containing ART (i.e., Atripla) can decrease (rather than increase) the systemic exposure of anticonvulsants (i.e., carbamazepine, phenytoin) since it is an inducer of CYP3A4. Thus, if efavirenz is introduced to a patient on a stable anticonvulsant regimen containing carbamazepine or phenytoin, the metabolism of the anticonvulsant is induced, and efficacy could be compromised. By the same mechanism, anticonvulsants can also decrease plasma levels of efavirenz as they too are inducers of CYP3A4 (12) .
Supplementary Table 1 (Supplemental Digital Content 1, http://links.lww.com/CCM/D327) provides examples of drug interactions. Such interactions are also described online in more detail (7) .
CONCLUSIONS
The astonishing development of effective and durable ART over the past 20 years has provided an opportunity for HIVinfected persons to attain the life expectancy of their HIVuninfected counterparts. Maintaining the activity of these life-saving regimens requires strategic decisions about drug absorption, drug-drug interactions, pharmacokinetics, and the advantages/disadvantages of drug-induced modulation of inflammatory and immunologic responses. Optimizing patient safety requires recognition of the toxicities of these agents as well. Critical care is a team endeavor, and management of ART is yet another example of the benefits of close collaboration between intensivists and their infectious disease and pharmacy colleagues.
